Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B007 in Generalized Myasthenia Gravis
NCT06447597Phase 3Recruiting
- Sponsor
- Shanghai Cross-linked Pharmaceutical Research and Development
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of B007 in myasthenia gravis (MG), sponsored by Shanghai Cross-linked Pharmaceutical Research and Development. Started Jul 2024; status: recruiting.
02
Drugs
B007
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06447597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06447597.